<DOC>
	<DOCNO>NCT00920946</DOCNO>
	<brief_summary>The purpose study determine Dimebon safe effective treatment cognitive impairment Huntington disease .</brief_summary>
	<brief_title>A Safety Efficacy Study Dimebon Patients With Huntington Disease</brief_title>
	<detailed_description>This study multicenter Phase 3 , randomize , double-blind , placebo-controlled safety efficacy study Dimebon treatment subject Huntington disease ( HD ) . The study evaluate Dimebon 20 mg three time daily ( TID ) administer orally ( PO ) six month ( 26 week ) compare match placebo TID primary safety efficacy analysis . Safety tolerability assess record adverse event monitor vital sign , physical examination , safety laboratory evaluation , 12-lead electrocardiogram ( ECG ) assessment .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Have clinical feature HD CAG polyglutamate repeat expansion â‰¥ 36 Have cognitive impairment note follow : 1 . A Screening MMSE AND baseline ( predose ) MMSE score 10 26 ( inclusive ) ; 2 . A subjective assessment cognitive impairment decline preHD level Investigator interview subject caregiver ; Are willing able give inform consent Aged 30 year old Have caregiver assists/spends time subject least five day per week least three hour per day intimate knowledge subject 's cognitive , functional , emotional state , subject 's personal care . Had onset symptom prior age 18 Have major medical illness unstable medical condition within 180 day screen may interfere subject 's ability comply study procedure abide study restriction , ability interpret safety data</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Huntington</keyword>
	<keyword>Dimebon</keyword>
	<keyword>HD</keyword>
	<keyword>Huntingtin</keyword>
</DOC>